China Pharmaceutical Excipients Industry Report, 2014-2017
  • Nov.2014
  • Hard Copy
  • USD $2,500
  • Pages:101
  • Single User License
    (PDF Unprintable)       
  • USD $2,300
  • Code: ZLC011
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,600
  • Hard Copy + Single User License
  • USD $2,700

Pharmaceutical excipients refer to adjuvants and additives used for production of pharmaceuticals and compounding of prescriptions. In addition to active ingredients, pharmaceutical excipients are also contained in pharmaceutical preparations after reasonable safety assessment.

China has launched more than 500 types of pharmaceutical excipients, far less than 1,500 types of the United States and 3,000 types of Europe. By market size, gelatin capsules, sucrose, starch, film-coated powder, 1,2-propylene glycol, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), microcrystalline cellulose, hydroxypropyl cellulose (HPC) and lactose rank as the top 10 pharmaceutical excipients in China.

Among them, the traditional pharmaceutical excipients --gelatin capsules are involved with adequate supply and large export volume. In H1 2014, China’s gelatin capsule export volume amounted to 1,427.5 tons and the export value hit USD32.408 million. However, China still relies on the import of film-coated powder, polyvinylpyrrolidone (PVP) and other new-type high-end pharmaceutical excipients.

Currently, pharmaceutical excipients account for about 2%-3% of China's total output value of pharmaceutical preparations. Chinese pharmaceutical excipient market size reached about RMB26.35 billion in 2013 and is expected to be RMB54.83 billion in 2017.

There are about 400 pharmaceutical excipient manufacturers in China, of which over 90 ones or 23% specialize in the production of pharmaceutical excipients, while most of the remaining ones focus on chemical or food processing.

Currently, foreign leading pharmaceutical excipient companies, such as Colorcon (the USA), Degussa (Germany), Meggle (Germany) and Roquette (France), have set up joint ventures, wholly-owned companies or offices in China. Colorcon mainly provides film-coated products; Meggle pharmaceutical lactose, and Roquette pharmaceutical starch and polyols.

Chinese pharmaceutical excipient giants include Er-Kang Pharmaceutical, Sunhere Pharmaceutical Excipients, Dongbao Bio-Tech, Qinghai Gelatin, Shandong Liaocheng A Hua Pharmaceutical, Zhanwang Pharmaceutical and Qufu Tianli, but their market concentration rate is rather low. As a tycoon, Er-Kang Pharmaceutical only seized about 2.7% market share in 2013.

Ranking among the largest Chinese pharmaceutical excipient producers with the most complete types, Er-Kang Pharmaceutical holds 116 types of pharmaceutical excipients and the capacity of 45,000 tons or more. Over the past two years, the company has continued to enforce epitaxial expansion strategy and accelerate market layout. In March 2014, the company acquired 100% stake in Changsha Zhengyang Pharmaceutical Capsule and 51% stake in Hunan Dongting Citric Acid Chemicals. In addition, the company’s 180,000 tons/a medicinal cassava starch production project went into operation on March 31, 2014; the first phase of "South China Pharmaceutical Excipient Base Construction Project" has been completed and will realize production goal at the end of 2014.
Sunhere Pharmaceutical Excipients is a Chinese member of International Pharmaceutical Excipient Confederation (IPEC), mainly producing microcrystalline cellulose, hydroxypropyl cellulose, hypromellose and other 18 types of new-type pharmaceutical excipients with the capacity of 10,000 tons. On April 24, 2014, Sunhere Pharmaceutical Excipients planned to go public so as to raise funds for 7,100 tons/a new-type pharmaceutical excipient production line expansion project.

Zhanwang Pharmaceutical produces 28 types of pharmaceutical excipient products including carboxymethyl starch sodium, pre-gelatinized starch, hypromellose, microcrystalline cellulose, etc., with the capacity of over 10,000 tons. Some production bases of the company have passed the certification of the US FDA and the European COS. Now, export has contributed 25% to the company’s revenue.

药用辅料 英文_副本.png

The report includes the following aspects:
20120114.gifOperating environment (including economy, policies, barriers to entry, upstream and downstream environment) of China pharmaceutical excipient industry;
20120114.gifStatus quo, competition pattern, import & export and development trend of China pharmaceutical excipient industry;
20120114.gifOperation, pharmaceutical excipient business and prospects of 10 major Chinese pharmaceutical excipient companies;
20120114.gifDevelopment forecast and operation comparison between major enterprises in China pharmaceutical excipient industry.

1 Overview of Pharmaceutical Excipients
1.1 Overview
1.2 Classification

2 Operating Environment of China Pharmaceutical Excipient Industry
2.1 Economy
2.2 Policies
2.3 Entry Barriers
2.3.1 Qualification
2.3.2 R & D and Technology
2.3.3 Marketing Channels and Brands
2.3.4 Funds
2.4 Upstream and Downstream Environment
2.4.1 Upstream
2.4.2 Downstream

3 Development of China Pharmaceutical Excipient Industry
3.1 International Market
3.2 Status Quo
3.3 Competition Pattern
3.4 Import and Export
3.4.1 Import
3.4.2 Export
3.5 Breakdown Products
3.5.1 Pharmaceutical Gelatin
3.5.2 Hydroxypropyl Methyl Cellulose (HPMC)
3.5.3 Pharmaceutical Starch
3.5.4 Pharmaceutical Sucrose
3.5.5 Propanediol
3.6 Development Trend
3.6.1 Marketing Channels and Brand Building Are Strengthened
3.6.2 The Industry Heads toward Production Specialization and Standardization   
3.6.3 The Varieties of Pharmaceutical Excipients Increase 
3.6.4 Downstream Pharmaceutical Preparation Industry Boosts Pharmaceutical Excipient Industry
3.6.5 Industrial Concentration Rate Will Ascend Gradually
3.6.6 Technological Development Turns the Focus to Security, Functionality, Adaptability, Efficiency, etc.  
3.6.7 Composite Excipients Will Be One Development Direction of Pharmaceutical Excipients

4 Major Companies
4.1 Er-Kang Pharmaceutical  
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure 
4.1.4 Gross Margin  
4.1.5 R & D and Investment 
4.1.6 Pharmaceutical Excipient Business 
4.1.7 Forecast and Outlook 
4.2 Sunhere Pharmaceutical Excipients   
4.2.1 Profile 
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin  
4.2.5 R & D and Investment 
4.2.6 Output and Sales Volume 
4.2.7 Supply 
4.2.8 Forecast and Outlook 
4.3 Dongbao Bio-Tech   
4.3.1 Profile 
4.3.2 Revenue 
4.3.3 Revenue Structure 
4.3.4 Gross Margin  
4.3.5 R & D and Investment 
4.3.6 Pharmaceutical Excipient Business 
4.3.7 Forecast and Outlook 
4.4 Qinghai Gelatin 
4.4.1 Profile 
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Gross Margin  
4.4.5 Pharmaceutical Excipient Business 
4.4.6 Forecast and Outlook 
4.5 Shandong Head 
4.5.1 Profile 
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin  
4.5.5 R & D and Investment 
4.5.6 Pharmaceutical Excipient Business 
4.5.7 Output and Sales Volume 
4.5.8 Supply 
4.5.9 Forecast and Outlook 
4.6 Shandong Liaocheng A Hua Pharmaceutical
4.6.1 Profile 
4.6.2 Operation 
4.6.3 Pharmaceutical Excipient Business 
4.7 Zhanwang Pharmaceutical 
4.7.1 Profile 
4.7.2 Operation 
4.7.3 Pharmaceutical Excipient Business 
4.8 Qufu Tianli 
4.8.1 Profile 
4.8.2 Pharmaceutical Excipient Business 
4.9 North China Pharmaceutical 
4.9.1 Profile 
4.9.2 Operation 
4.9.3 Revenue Structure 
4.9.4 Pharmaceutical Excipient Business 
4.10 Joinway Pharmaceutical 
4.10.1 Profile 
4.10.2 Pharmaceutical Excipient Business

5 Forecast and Outlook 
5.1 Industrial Development Forecast 
5.2 Operation Comparison between Major Enterprises
5.2.1 Revenue 
5.2.2 Net Profit 
5.2.3 Net Profit Margin 
5.2.4 Gross Margin  
5.2.5 Pharmaceutical Excipient Business 
Classification of Pharmaceutical Excipients   
China's GDP and YoY Growth Rate, 1985-2014 
Policies and Regulations on China Pharmaceutical Excipient Industry 
China’s Corn Starch Output, 2009-2013
China’s Corn Starch Price, Oct-Nov 2014 
China’s Refined Cotton Price, Dec 2013-Apr 2014
China’s Chemical Preparation Manufacturing Revenue and YoY Growth, 2009-2013    
China’s Chinese Patent Medicine Manufacturing Revenue and YoY Growth, 2009-2013 
China’s Biological and Biochemical Manufacturing Revenue and YoY Growth, 2009-2013
China’s Pharmaceutical Excipient Market Size, 2009-2014
Structure of Chinese Pharmaceutical Excipient Enterprises (by Type)
Market Share of Major Chinese Pharmaceutical Excipient Companies, 2013
Products, Categories and Capacity of Major Chinese Pharmaceutical Excipient Companies, 2013
Top 10 Gelatin Capsule Import Sources of China by Import Volume and Value, 2013-2014
Top 10 Gelatin Capsule Export Destinations of China by Export Volume and Value, 2013-2014
Gelatin Consumption Structure (%) by Country / Region
China’s Gelatin Output Structure (by Type)
China’s Gelatin and Bone Gelatin Market Capacity, 2005-2014
China’s MC/HPMC Capacity, 2006-2013
China’s Pharmaceutical Cellulose Ether Demand, 2009-2016E
China’s Starch Output, 2009-2013
Proportion of China’s Starch Output (by Product)
China’s Starch Import and Export (by Product), 2013
China’s Medicinal Starch Quality Index
China’s Medicinal Starch Demand, 2011-2015E
China’s Sugar Output and YoY Growth Rate, 2006/07-2013/14  
Output Proportion of China's Main Sugar Producing Areas, 2013-2014
Quality Index Comparison between Medicinal Sucrose and White Sugar
China’s Propanediol Output and YoY Growth, 2005-2010     
China’s Propanediol Import and Export, Jan-Sep 2014
Revenue and Net Income of Er-Kang Pharmaceutical, 2009-2014
Revenue of Er-Kang Pharmaceutical (by Product), 2009-2014
Revenue Structure of Er-Kang Pharmaceutical (by Product), 2009-2014
Revenue of Er-Kang Pharmaceutical (by Region), 2009-2014
Revenue Structure of Er-Kang Pharmaceutical (by Region), 2009-2014
Gross Margin of Er-Kang Pharmaceutical, 2009-2014
Gross Margin of Er-Kang Pharmaceutical (by Product), 2009-2014
R & D Costs and % of Total Revenue of Er-Kang Pharmaceutical, 2009-2013
Completion of Fund-raising Projects of Er-Kang Pharmaceutical, 2013
Pharmaceutical Excipient Revenue and % of Total Revenue of Er-Kang Pharmaceutical, 2009-2014
Main Pharmaceutical Excipient Capacity of Er-Kang Pharmaceutical, 2013
Revenue and Net Income of Er-Kang Pharmaceutical, 2012-2017E
Revenue and Net Income of Sunhere Pharmaceutical Excipients, 2011-2013
Revenue of Sunhere Pharmaceutical Excipients (by Product), 2011-2013
Revenue Structure of Sunhere Pharmaceutical Excipients (by Product), 2011-2013
Revenue of Sunhere Pharmaceutical Excipients (by Region), 2011-2013
Revenue Structure of Sunhere Pharmaceutical Excipients (by Region), 2011-2013
Gross Margin of Sunhere Pharmaceutical Excipients, 2011-2013
R & D Costs and % of Total Revenue of Sunhere Pharmaceutical Excipients, 2011-2013
Fund-raising Projects of Sunhere Pharmaceutical Excipients and Allocation of Raised Funds
Capacity, Capacity Utilization and Sales-Output Ratio of Main Products of Sunhere Pharmaceutical Excipients, 2011-2013
Top Five Customers of Sunhere Pharmaceutical Excipients in Basic Raw Material Products, 2011-2013
Top Five Customers of Sunhere Pharmaceutical Excipients in Crude-product Fine Processing Products, 2011-2013
Top Five Suppliers of Sunhere Pharmaceutical Excipients in Basic Raw Material Production, 2011-2013
Top Five Suppliers of Sunhere Pharmaceutical Excipients in Excellent-product Fine Processing and Production, 2011-2013
Revenue and Net Income of Sunhere Pharmaceutical Excipients, 2012-2017E 
Revenue and Net Income of Dongbao Bio-Tech, 2010-2014
Revenue of Dongbao Bio-Tech (by Product), 2010-2014
Revenue of Dongbao Bio-Tech (by Region), 2011-2014
Revenue Structure of Dongbao Bio-Tech (by Region), 2011-2014
Gross Margin of Dongbao Bio-Tech, 2011-2014
Gross Margin of Dongbao Bio-Tech (by Product), 2011-2014
Gross Margin of Dongbao Bio-Tech (by Region), 2011-2013
R & D Costs and % of Total Revenue of Dongbao Bio-Tech, 2011-2013
Completion of Fund-raising Projects of Dongbao Bio-Tech, 2013
Pharmaceutical Gelatin Revenue of Dongbao Bio-Tech, 2010-H1 2014
Revenue and Net Income of Dongbao Bio-Tech, 2012-2017E 
Revenue and Net Income of Qinghai Gelatin, 2010-2014
Revenue of Qinghai Gelatin (by Product), 2010-2014
Revenue of Qinghai Gelatin (by Sector), 2010-2014
Revenue of Qinghai Gelatin (by Region), 2011-2014
Revenue Structure of Qinghai Gelatin (by Region), 2011-2014
Gross Margin of Qinghai Gelatin, 2010-2014
Gross Margin of Qinghai Gelatin (by Product), 2010-2014
Gross Margin of Qinghai Gelatin (by Region), 2012-2014
Pharmaceutical Excipient Revenue and% of Total Revenue of Qinghai Gelatin, 2010-2014
Revenue and Net Income of Qinghai Gelatin, 2012-2017E
Classification and Properties of Cellulose Ether
Revenue and Net Income of Shandong Head, 2011-2013
Revenue of Shandong Head (by Product), 2011-2013
Revenue Structure of Shandong Head (by Product), 2011-2013
Revenue of Shandong Head (by Region), 2011-2013
Revenue Structure of Shandong Head (by Region), 2011-2013
Domestic Revenue of Shandong Head (by Region), 2011-2013
Overseas Revenue of Shandong Head (by Region), 2011-2013
Gross Margin of Shandong Head, 2011-2013
Gross Margin of Shandong Head (by Product), 2011-2013
R & D Costs and % of Total Revenue of Shandong Head, 2011-2013
Fund-raising Projects of Shandong Head and Allocation of Raised Funds
Pharmaceutical Excipient Revenue, % of Total Revenue and Gross Margin of Shandong Head, 2011-2013
Capacity, Output and Sales Volume of Main Products of Shandong Head, 2011-2013
Diacetone Acrylamide Capacity, Output and Sales Volume of Shandong Head, 2011-2013
Top Five Customers of Shandong Head, 2011-2013
Top Five Suppliers of Shandong Head, 2011-2013
Revenue and Net Income of Shandong Head, 2012-2017E 
Total Assets, Revenue and Net Income of Shandong Liaocheng A Hua Pharmaceutical, 2010-2014
Capacity and Application of Main Products of Shandong Liaocheng A Hua Pharmaceutical
Revenue of Zhanwang Pharmaceutical, 2012-2016E
Capacity of Main Pharmaceutical Excipient Products of Qufu Tianli
Revenue and Net Income of North China Pharmaceutical, 2009-2014
Revenue of North China Pharmaceutical (by Product), 2009-2014
Revenue Structure of North China Pharmaceutical (by Product), 2009-2014
Revenue of North China Pharmaceutical (by Region), 2009-2014
Revenue Structure of North China Pharmaceutical (by Region), 2009-2014 
Chinese Pharmaceutical Excipient Market Size, 2012-2017E
Revenue of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Net Income of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Net Profit Margin of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Gross Margin of Major Companies in China Pharmaceutical Excipient Industry, 2009-2013
Pharmaceutical Excipient Revenue of Major Chinese Pharmaceutical Excipient Companies, 2009-2013

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号